11/16/2026 | Press release | Distributed by Public on 11/16/2026 11:35
CNX Therapeutics Limited ("CNX Therapeutics"), a specialty pharmaceutical company committed to improving access to essential medicines, has signed an exclusive distribution agreement with BTC Pharma Pty Ltd ("BTC Pharma"), a wholly owned investee company of ASX-listed BTC Health Limited, for Sativex® (nabiximols) oromucosal spray in Australia and New Zealand.
Under the agreement, BTC Pharma will become the marketing authorisation holder in both countries and will take responsibility for regulatory compliance, pharmacovigilance, medical information, market access and sales. CNX Therapeutics will continue to manufacture and supply Sativex from the UK. The initial term is five years, with an option to extend for a further two years by agreement.
Sativex is indicated for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not adequately responded to other anti-spasticity medication. It has been approved in New Zealand since 2010 and registered in Australia since 2012. It is one of only two medicinal cannabis products on the Australian Register of Therapeutic Goods, meaning the Therapeutic Goods Administration has assessed its quality, safety and efficacy.
BTC Pharma and CNX Therapeutics will now transfer the registrations and supply arrangements, with continuity of supply for existing patients as the first priority. Once the transition is complete, BTC Pharma plans to re-engage prescribing specialists in neurology and rehabilitation medicine.
The agreement extends CNX Therapeutics' Sativex footprint beyond the UK. It follows the distribution partnership for Canada with Innomar Strategies, a part of Cencora, effective 31 July 2026, and CNX Therapeutics' acquisition of the global Sativex business from Jazz Pharmaceuticals in November 2025.
Prescribing information for Sativex® is available on request.
ENDS
Notes to editors
For more information, please contact [email protected]
About CNX Therapeutics
CNX Therapeutics is a specialty pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. It commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 60 markets worldwide, both directly and through strategic partnerships. Sativex® is a registered trademark of CNX Therapeutics Limited. For more information, visit www.cnx-therapeutics.com.
About BTC Health
BTC Health Ltd is a Pooled Development Fund that makes active investments in businesses which acquire, develop and distribute innovative medical products in Australia and New Zealand. It is listed on the Australian Securities Exchange (ASX: BTC). For more information, visit www.btchealth.com.au.